Synonym
Win 33377; Win33377; Win-33377
IUPAC/Chemical Name
Methanesulfonamide, N-((1-((2-(diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)-
InChi Key
NAMOLZVVTPNNTE-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H27N3O3S2/c1-4-24(5-2)13-12-22-17-11-10-15(14-23-29(3,26)27)21-19(17)20(25)16-8-6-7-9-18(16)28-21/h6-11,22-23H,4-5,12-14H2,1-3H3
SMILES Code
CS(=O)(NCC1=CC=C(NCCN(CC)CC)C(C2=O)=C1SC3=C2C=CC=C3)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
433.59
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Izbicka E, Lawrence R, Davidson K, Rake JB, Von Hoff DD. Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells. Invest New Drugs. 1998-1999;16(3):221-5. doi: 10.1023/a:1006152100299. PMID: 10360601.
2: Drozd ML, Lockwood G, Miller B, Rosi D. A column-switching high-performance liquid chromatographic assay for a novel cytotoxic thioxanthone derivative (WIN 33377) in mouse plasma with toxicokinetic results from a mouse LD10 study. J Chromatogr B Biomed Appl. 1995 Aug 4;670(1):145-51. doi: 10.1016/0378-4347(95)00155-c. PMID: 7493072.
3: Cao LY, Huang H, Ni JH. [Progress in researches on drugs for prostate cancer]. Zhonghua Nan Ke Xue. 2003 Dec;9(9):703-6. Chinese. PMID: 14727365.
4: LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH. Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res. 2000 Aug;6(8):3088-94. PMID: 10955788.
5: Stevenson JP, DeMaria D, Reilly D, Purvis JD, Graham MA, Lockwood G, Drozd M, O'Dwyer PJ. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule. Cancer Chemother Pharmacol. 1999;44(3):228-34. doi: 10.1007/s002800050971. PMID: 10453724.
6: Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity. Clin Cancer Res. 1997 Nov;3(11):2047-53. PMID: 9815596.
